• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

A comprehensive update of the 2005 edition

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion

The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer's recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population.

The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016.

The World Market for Addiction Disorders, 2009 2016: Future Therapies for Substance Dependence and Impulse Control, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipeline drugs, company activities, and addiction disorder demographics.

Therapy area forecasting and illustrative comparative sales data is presented to gain insight into leading products with sales estimates to 2016.

Objectives of Report
The objectives of this 80 page report are to provide an in-depth analysis of the global addiction pharmacotherapeutic market. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. The reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Report Highlights Include:

• The current market for addiction disorders is valued at US$3.2 billion, up from US$2 billion in 2005
• Critical analysis of alcohol, cocaine, opiate, and nicotine addictions
• Review of epidemiological, aetiological, and demographic data for addiction disorders
• Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders
• Sales estimates (US$) to 2012 for major therapy areas
• Strategic insights for life-cycle optimization and product development
• Critical evaluation of leading addiction pharmacotherapies
• Emerging markets identified and sector analysis
• Trend analysis of industry events and activities over past 2 years
• Detailed R&D themes and clusters by addiction area
• Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
• High revenue-yielding prospects identified with projected sales estimations
• R&D pipeline positioning for novel candidates
• Market insights for product development and drug promotion
  

What you can learn from this report:

• Which addiction therapies are the current and potential future market leaders
• How companies are reformulating products for addiction indications
• Which premarket addiction pharmacotherapies are identified as high-value products
• Which companies are developing drugs for addiction disorders
• Sales predictions to 2016 for addiction pharmacotherapies
• What the likely impact of pipeline products will be on value growth of the addiction market over the 10 years
• Which addiction subsectors could be niche market opportunities
• What the future outlook holds for addiction pharmacotherapies
• Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
• Which molecules and compounds are main R&D clusters for dependency disorders
• Which of the pipeline candidates are top prospects in the addiction market over the next decade and to 2025

Report Contains:

• Detailed survey and analysis of the current and future global addiction disorder market
• Comprehensive update on key marketed products indicated for alcohol, narcotic, and nicotine dependency disorders
• Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
• Market analysis and insight of key addiction pharmacotherapies and pipelines
• Market value predictions of individual marketed products to 2016
• Insight and trend analysis of pipeline products for addiction disorders
• Review of promising pipeline products and potential market opportunities
• Extensive coverage of the R&D pipeline for addiction disorders
• Guide to leads for potential licensing opportunities
  

Companies Mentioned in this Report include
Acrux
Alkermes
Biotie Therapies
Brookwood Pharmaceuticals
Catalyst Pharma Partners
Celtic Pharmaceuticals
Cephalon
Drug Abuse Sciences
Elbion
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Impax Laboratories
InterveXion Therapeutics
J&J
Janssen-Cilag
Krele Pharma
Merck Serono
Nabi Biopharmaceuticals
Pfizer
Sanofi-Aventis
Somaxon Pharma.
STADA
Synosia Therapeutics
Targacept
Teva Pharmaceuticals
Titan Pharmaceuticals
WorldMeds
Yaupon Therapeutics

Chapter 1. Introduction to Addiction Disorders
Addiction: Substance Characteristics and Prevalence of Misuse
Neurobiological Basis of Addiction
Prevalence of Substance Misuse - Estimates for North America, Europe and Asia

Incidence Estimates for Addiction Disorders in North America, Europe, and Japan
Treatment Options

Chapter 2. The Addiction Pharmacotherapy Market
Market Overview for Addiction Disorders
Market Forecasts by Therapeutic Area
Chapter 3. Alcohol Addiction Market
Alcohol Addiction
Pipeline Focus for Alcohol Addiction - Biotie Therapies Corp
Alcohol Addiction - Market Insights and Future Considerations

Chapter 4. The Narcotic Addiction Market
Global Narcotics - Usage Statistics
Narcotic Addiction - The Scale of the Problem
Pharmacotherapies for Narcotic Addiction - Market Evaluation
Opioid Addiction Pharmacotherapies
Drugs to Control Opioid Withdrawal Symptoms
Therapeutic Switching in Addiction Markets
Outlook for Pharmacotherapeutic Markets Related to Alcohol and Narcotic Abuse

Chapter 5. Tobacco Addiction
Prevalence and Mortality Statistics
Nicotine: Mechanism of Action
Tobacco Dependence and Smoking Cessation
Smoking and Health Consequences
Tobacco Addiction Pharmacotherapeutics
Market Analysis of Smoking Cessation Pharmacotherapeutics
Nicotine Replacement Therapies
Nicorette/Nicotrol - McNeil Healthcare/Johnson & Johnson
Sales Estimates

Tobacco Addiction - Market Insights and Future Considerations

Chapter 6. Drugs in Research and Development
Addiction Disorders - Research and Development Overview
Pipeline Addiction Pharmacotherapies
Alcohol Dependence
Cocaine Dependence
Novel Late-Stage Candidates
Opioid Dependence
Impulse Control Disorders
Pipeline Focus - Gambling Addiction
Tobacco/Nicotine Dependence
Pipeline Focus on Immunotherapies for Tobacco Dependence
Smoking Cessation - A Transforming Market

Chapter 7. Market Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Therapy Area Forecasts
Prospect Mining
Therapy Area Forecasts 2016 and 2025

Chapter 8. Summary and Key Data Points on the Addiction Market
Key Data Points
Reference Sources



List of Tables
Table 1.1 Neurotransmitter Systems Associated with Addiction
Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
Table 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009 (000' users)
Table 1.4 Estimated Incidence for Addiction Disorders in North America, Europe and Japan, 2009 (incidence in 000s)
Table 2.1 Market Synopsis for Addiction Disorders: Current data
Table 2.2 Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2008-2016
Table 3.1 Physiological Consequences of the Disulfiram-Alcohol Reaction
Table 5.1 Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2008-2016
Table 6.1 Drugs in Development/Trials for Alcohol Dependence, 2009
Table 6.2 Drugs in Development/Trials for Cocaine Dependence, 2009
Table 6.3 Drugs in Development/Trials for Cannabis Dependence, 2009
Table 6.4 Drugs in Development/Trials for Ampetamine and Phencyclidine Dependencies, 2009
Table 6.5 Drugs in Development/Trials for Opioid Dependence, 2009
Table 6.6 Drugs in Development/Trials for Impulse Control Disorders, 2009
Table 6.7 Drugs in Development/Trials for Tobacco Addiction, 2009
Table 7.1 Estimated Global Drug Market (US$m) and Growth Rate (%) for Addiction Pharmacotherapies, 2008-2016
Table 7.2 Therapy Area Forecasts for the World Addiction Disorders Market, 2016 and 2025


List of Figures
Figure 1.1 Estimated Prevalence of Substance Misuse in United States, 2009
Figure 1.2 stimated Prevalence of Substance Misuse in Canada, 2009
Figure 1.3 Estimated Prevalence of Substance Misuse in Europe, 2009
Figure 1.4 Estimated Prevalence of Substance Misuse in Japan, 2009
Figure 2.1 Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2008-2016
Figure 2.2 Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 2009 & 2016
Figure 7.1 Comparative Analysis of Leading Addiction Pharmacotherapies, 2008-2016 (US$m)
Figure 7.2 Key Addiction Disorder Pharmacotherapy Prospects, 2009

 

Companies Mentioned Include:

Acrux
Alkermes
Biotie Therapies
Brookwood Pharmaceuticals
Catalyst Pharma Partners
Celtic Pharmaceuticals
Cephalon
Drug Abuse Sciences
Elbion
Eli Lilly
Forest Laboratories
GlaxoSmithKline
Impax Laboratories
InterveXion Therapeutics
J&J
Janssen-Cilag
Krele Pharma
Merck Serono
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals
Pfizer
Sanofi-Aventis
Somaxon
Somaxon Pharma.
STADA
Synosia Therapeutics/Roche
Synosia Therarapeutics
Targacept
Teva Pharmaceuticals
Titan Pharmaceuticals
WorldMeds
Yaupon Therapeutics

Tim Atkinson has authored over 30 pharmaceutical market research reports and has expertise in drug discovery, drug development and drug delivery in addition to generics, parallel trade, and numerous therapeutic areas such as hormonal and metabolic disorders, oncology, and infection.
 
He has undertaken assignments for leading pharmaceutical companies such as Pfizer and GlaxoSmithKline, as well as for healthcare agencies and publishers such as Global Business Insights, IMS Health, and Informa Healthcare.

He worked previously as a Biomedical Scientist within the UK NHS and is a trained Medical Writer/Editor and has worked for publishers such as Thomson Science, Mosby, Churchill Livingstone and Current Science Group.

Tim founded the specialist biopharma market research firm Spectra Intelligence in 2004, which was acquired by URCH Publishing in 2009.

He holds an MSc in Health and Disease from Birkbeck College, London and he is a member of the Royal Society of Chemistry, Institute of Biology, and British Society for Immunology